4SC AG: Positive safety review of Phase Ib/II EMERGE study of domatinostat + avelumab in gastrointestinal cancer
4SC AG (4SC, FSE Prime Standard: VSC) today announced, that the Safety Review Committee consisting of clinical and drug safety experts evaluated the safety data from the third and final dose cohort and recommended continuation into the expansion phase of Mehr



